SEC Form 4 · accession 0001961994-26-000024
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Anthony Williams
Officer — SVP, Products Business
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 12:57 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 1, 2026 | S | 3,000 | $8.40 | D | 159,098 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.